Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Aytu Biopharma (AYTU) Other Gross PP&E Adjustments (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with -$24000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 99.04% to -$24000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$24000.0, a 99.04% increase, with the full-year FY2025 number at -$201000.0, down 127.53% from a year prior.
  • Other Gross PP&E Adjustments was -$24000.0 for Q4 2025 at Aytu Biopharma, up from -$126000.0 in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $3.7 million in Q1 2023 to a low of -$9.0 million in Q3 2021.
  • A 5-year average of -$1.0 million and a median of -$254000.0 in 2022 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: tumbled 7406.14% in 2021, then skyrocketed 10841.18% in 2023.
  • Aytu Biopharma's Other Gross PP&E Adjustments stood at -$6.8 million in 2021, then skyrocketed by 95.46% to -$307000.0 in 2022, then plummeted by 286.64% to -$1.2 million in 2023, then tumbled by 111.12% to -$2.5 million in 2024, then skyrocketed by 99.04% to -$24000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Gross PP&E Adjustments are -$24000.0 (Q4 2025), -$126000.0 (Q3 2025), and -$201000.0 (Q2 2025).